營業時間
-
星期日
店休
-
星期一
上午9:00 - 下午5:30
-
星期二
上午9:00 - 下午5:30
-
星期三
上午9:00 - 下午5:30
-
星期四
上午9:00 - 下午5:30
-
星期五
上午9:00 - 下午5:30
-
星期六
店休
公司資訊
Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. U.S. FDA approval and registration, subject to ongoing clinical success, is being pursued for each drug and therapy under development. Each indication under investigation currently has no, or limited, existing registered pharmacotherapy (drug) treatments available to the public and represent major global economic opportunities to Incannex and its shareholders. Incannex has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. The Company holds 19 granted patents and 30 pending patent applications. Incannex is listed on the Australian Stock Exchange (ASX) with stock code “IHL” and has American Depository Shares listed on NASDAQ under code “IXHL”.團隊組成
Joel Latham
熱門服務
Incannex Healthcare
60 分鐘
評論
0 客戶評論